Company intelligence / Profile preview

Cytheris SA

Issy-les-Moulineaux, Francenewswire.ca ↗

Ownership: Private
Employees: ~33
Development stage: Phase 2

Overview

Clinical trials conducted on more than 240 patients demonstrated the ability of CYT107 to expand and protect CD4+ and CD8+ T-cells in various pathologic conditions with a consistent safety and tolerability profile. In HIV patients, a Phase I/II study showed that after 48 weeks, patients treated at the higher dose level had a median increase in CD4+ and CD8+ T-cell counts of 75% and 57%, respectively, from baseline levels.

Therapeutic areas: OncologyImmunologyHematologyNeurologyInfectious Diseases
Modalities: Recombinant human Interleukin-7 (r-hIL-7, CYT107)
Industry: Biotech

Drug pipeline

1 asset

CYT107

Phase 2

Indications: HIV, Hepatitis B, Hepatitis C, Cancer, Progressive Multifocal Leukoencephalopathy, Lymphopenia

Beyond the preview

Go deeper on Cytheris SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytheris SA.

Explore the full profile